Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Plexium, a biotech firm devoted to finding small molecules that induce protein degradation, has launched with $28 million from its first formal funding round. The San Diego–based firm will use DNA-encoded libraries to conduct cell-based screens for molecules that can prompt E3 ligases to raise or lower levels of specific proteins. Plexium’s first goal is to modulate proteins implicated in cancer and neurodegenerative diseases.
This article has been sent to the following recipient: